Kiniksa Pharmaceuticals Ltd reports results for the quarter ended in December - Earnings Summary

Kiniksa Pharmaceuticals International

28/02/2023 14:09

* Kiniksa Pharmaceuticals Ltd  KNSA.OQ  reported quarterly
adjusted earnings of 6 cents​​ per share for the quarter ended
in December. The mean expectation of four analysts for the
quarter was for a loss of 23 cents per share.
    * Revenue rose 230.1% to $61.88 million from a year ago;
analysts
expected $45.12 million. 
    * Kiniksa Pharmaceuticals Ltd's reported EPS for the quarter
was 6
cents​.
    * The mean earnings estimate of analysts had fallen by
about 4.5%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Kiniksa Pharmaceuticals Ltd shares had fallen by 11.1%
this
quarter.
    * The company reported quarterly net income of $4.46
million.
    * Wall Street's median 12-month price target for Kiniksa
Pharmaceuticals Ltd is $20.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
28 at 02:08 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.23          0.06           Beat
 Sep. 30 2022      0.78           3.18           Beat
 Jun. 30 2022      -0.44          -0.29          Beat
 Mar. 31 2022      -0.41          -0.36          Beat